Etrolizumab clinical trials

Studies by the year they started

13 studies that test it; most in 2014 (6)

Who runs them

Industry 13 · Other 0

Hoffmann-La Roche (9) · Genentech, Inc. (4)

Studies

Open first, then newest update. How each study uses etrolizumab is read from its arms, and is right about nine times in ten.

Testing it · 13

• A Phase I Study of Etrolizumab Followed by Open-Label Extension and Safety Monitoring in Pediatric Patients With Moderate to Severe Ulcerative Colitis or Moderate to Severe Crohn's DiseaseTerminatedPhase 1Hoffmann-La RocheNCT03478956Written as Etrolizumab
• Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144TerminatedPhase 3Hoffmann-La RocheNCT02403323Written as Etrolizumab
• Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III StudiesTerminatedPhase 3Hoffmann-La RocheNCT02118584Written as Etrolizumab
• A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's DiseaseCompletedPhase 3Hoffmann-La RocheNCT02394028Written as Etrolizumab
• A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Naïve to Tumor Necrosis Factor (TNF) InhibitorsCompletedPhase 3Hoffmann-La RocheNCT02136069Written as Etrolizumab
• A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) InhibitorsCompletedPhase 3Hoffmann-La RocheNCT02165215Written as Etrolizumab
• A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) InhibitorsCompletedPhase 3Hoffmann-La RocheNCT02100696Written as Etrozulimab
• A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) InhibitorsCompletedPhase 3Hoffmann-La RocheNCT02171429Written as Etrolizumab
• A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) InhibitorsCompletedPhase 3Hoffmann-La RocheNCT02163759Written as Etrolizumab
• Study to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative ColitisCompletedPhase 2Genentech, Inc.NCT01461317Written as Etrolizumab
• A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of rhuMAb Beta7 in Patients With Ulcerative ColitisCompletedPhase 1Genentech, Inc.NCT00694980Written as rhuMAb Beta7
• A Study to Evaluate Pain, Tolerability, Safety, and Usability of a Single Self-administered Etrolizumab by Auto-injector in Healthy ParticipantsCompletedPhase 1Genentech, Inc.NCT02629744Written as Etrolizumab
• Evaluate the Efficacy and Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative ColitisCompletedPhase 2Genentech, Inc.NCT01336465Written as rhuMAb Beta7

Codes

What other systems call etrolizumab · ClinicalTrials.gg INT005859

• MeSH (NLM) C559198etrolizumabConfirmed ClinicalTrials.gov, NLM, Wikidata
• UNII (FDA) I2A72G2V3JETROLIZUMABConfirmed FDA, NLM, Wikidata
• Wikidata Q5404888etrolizumabConfirmed FDA, NLM, Wikidata
• NCI Thesaurus C97944EtrolizumabOne source FDA
• DrugBank DB12189One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.